Antitumor action of bovine seminal ribonuclease
Language English Country United States Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
9821313
DOI
10.1007/bf02820807
Knihovny.cz E-resources
- MeSH
- Endoribonucleases administration & dosage therapeutic use MeSH
- Neoplasms, Experimental drug therapy MeSH
- Melanoma drug therapy MeSH
- Mice, Nude MeSH
- Mice MeSH
- Prostatic Neoplasms drug therapy MeSH
- Antineoplastic Agents administration & dosage therapeutic use MeSH
- Drug Screening Assays, Antitumor MeSH
- Seminoma drug therapy MeSH
- Cattle MeSH
- Transplantation, Heterologous MeSH
- Neoplasm Transplantation MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Mice MeSH
- Cattle MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Endoribonucleases MeSH
- Antineoplastic Agents MeSH
- ribonuclease SPL MeSH Browser
Unlike the bovine pancreatic ribonuclease (RNAase A), bovine seminal ribonuclease (BS RNAase) displays various biological activities including antitumor cytotoxicity. To learn more about its antitumor activity, we investigated BS RNAase effect on athymic nude mice bearing various tumors. BS RNAase (250 micrograms per mouse per day) was administered to the mice with prostate carcinoma for three weeks by three different routes (intraperitoneally--i.p., subcutaneously--s.c., and intratumorally-i.t.). Administration i.p. was ineffective, while s.c. administration reduced significantly size of tumors and i.t. administration abolished half of the tumors in treated mice. The i.t. administration of BS RNase to nude mice bearing melanoma showed even better results. Eighty % of mice were without tumors and in the other mice the tumors were significantly diminished. The best antitumor effect was obtained in case of seminoma. All mice bearing this tumor were cured after ten doses of BS RNAase.
